Santen Pharmaceutical Co., Ltd. (TYO: 4536)
Japan
· Delayed Price · Currency is JPY | Market Cap | 532.85B |
| Revenue (ttm) | 302.56B |
| Net Income (ttm) | 26.12B |
| Shares Out | 341.35M |
| EPS (ttm) | 73.03 |
| PE Ratio | 21.37 |
| Forward PE | 15.02 |
| Dividend | 34.00 (2.21%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 857,500 |
| Average Volume | 1,435,860 |
| Open | 1,551.00 |
| Previous Close | 1,536.00 |
| Day's Range | 1,540.50 - 1,566.50 |
| 52-Week Range | 1,394.50 - 1,878.50 |
| Beta | 0.21 |
| RSI | 42.33 |
| Earnings Date | Feb 6, 2025 |
About Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2α derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in pha... [Read more]
Financial Performance
Financial StatementsNews
Santen Pharmaceutical Co., Ltd. (SNPHY) Management on Q1 2022 Results - Earnings Call Transcript
Santen Pharmaceutical Co., Ltd. (OTCPK:SNPHY) Q1 2022 Earnings Conference Call August 4, 2022 3:30 AM ET Company Participants Peter Sallstig - Chief Medical Officer Conference Call Participants Peter ...